GFUS

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, GFUS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GFUS data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher GFUS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GFUS expression acts as an unfavorable survival marker.

SARC, UCEC, and PRAD are the cancer types where GFUS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SARCOSMedianAll0.1080.839<.00112view →
UCECOSMedianIII,IV0.0610.588.01812view →
PRADDFSMedianAll0.0850.774<.0016view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GFUS–SARC (OS)

Kaplan–Meier survival curve for GFUS mutant vs wild-type samples in SARC.

Open the SARC breakdown →

Exploration